177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial? - sprookjes - yvandenbroek - TriplyDB

177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

http://www.wikidata.org/entity/Q48257941

about

Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine

P2860

Q57107703-FD72C7BF-5C41-4D4F-9C7D-567313F0459A

P2860

177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

http://www.wikidata.org/entity/Q48257941

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

@de

177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

@en

177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

@nl

type

label

177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

@de

177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

@en

177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

@nl

prefLabel

177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

@de

177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

@en

177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

@nl

P1433

Q48257941-C992F6BF-ABFA-4091-960C-2BA9F2EB2F78

P1476

Q48257941-F273E942-94E6-4F0B-8AAC-BCAAC4E36266

P2093

Q48257941-7EBA89F0-14CE-4C68-B753-D9D270CB7A86

P2860

Q48257941-049DFEDB-0CD3-40C3-BFC7-59A092F3527C

Q48257941-1FC062E5-FB9C-44D3-987E-1FF157C63BD8

Q48257941-74D998C7-105F-4A3E-AFB4-1DBF7C103CDC

Q48257941-A28AC324-F4EF-4C0F-BB78-35EC9985E530

P2888

Q48257941-6CC9B43B-9F6E-4DB6-AB01-B0CCEC79562D

P304

Q48257941-F844C894-2722-4B5A-9777-BEF71E0014BE

P31

Q48257941-DC25A63D-16A1-4736-B8FB-61B4F3047250

P356

Q48257941-8B0742D2-6DC7-4795-BD71-862845971BC2

P433

Q48257941-A812A2F0-FC9F-42FF-896D-AEC89E91B66C

P478

Q48257941-C2111205-5004-4343-BFDC-93F576DE6668

P50

Q48257941-93D6578E-2889-42EF-8E51-E03EEE32276B

Q48257941-D6D42B00-2FEB-44D8-8BAD-54CA621DA005

P577

Q48257941-AA9A8F2A-2011-40BA-8D56-BCFFF0C67F9D

P698

Q48257941-10FEC946-4079-4131-AA6D-8F721CA6B1A2

P921

Q48257941-DF0B7AA6-E55A-488D-ADF4-B623F53FBC4A

P356

S00259-017-3892-0

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

@en

P2093

Martin Boegemann

http://www.w3.org/2001/XMLSchema#string

P2860

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.

P2888

s00259-017-3892-0

P304

513-514

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-017-3892-0

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P50

Hojjat Ahmadzadehfar

P577

2017-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29164300

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial